Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

BACKGROUND: To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Grijalba, Virginia, Arbizu, Javier, Romero, Judith, Prieto, Elena, Pesini, Pedro, Sarasa, Leticia, Guillen, Fernando, Monleón, Inmaculada, San-José, Itziar, Martínez-Lage, Pablo, Munuera, Josep, Hernández, Isabel, Buendía, Mar, Sotolongo-Grau, Oscar, Alegret, Montserrat, Ruiz, Agustín, Tárraga, Lluis, Boada, Mercè, Sarasa, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886187/
https://www.ncbi.nlm.nih.gov/pubmed/31787105
http://dx.doi.org/10.1186/s13195-019-0549-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886187/
https://www.ncbi.nlm.nih.gov/pubmed/31787105
http://dx.doi.org/10.1186/s13195-019-0549-1

Ejemplares similares